M1 macrophage features in severe Plasmodium falciparum malaria patients with pulmonary oedema

Aekkarin Klinkhamhom1, Supattra Glaharn1, Charit Srisook1

  • 1Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand.

Malaria Journal
|May 17, 2020
PubMed
Abstract

Insights

Severe malaria with pulmonary oedema shows increased M1 macrophage polarization in the lungs. This finding in Plasmodium falciparum malaria may guide therapies to mitigate lung injury.

Area of Science:

  • Immunology
  • Pathology
  • Infectious Diseases

Background:

  • Pulmonary oedema (PE) is a severe complication of Plasmodium falciparum malaria, potentially leading to acute lung injury.
  • Lung macrophages play a role in malaria infection's immune response, but their polarization (M1/M2 subtypes) in PE is not well understood.
  • Understanding macrophage polarization in malaria could inform new therapeutic strategies for lung involvement.

Purpose of the Study:

  • To investigate the polarization of lung macrophages (M1 vs. M2) in patients with severe Plasmodium falciparum malaria.
  • To compare macrophage polarization in patients with and without pulmonary oedema.

Main Methods:

  • Analysis of lung tissue samples from deceased patients with severe P. falciparum malaria, categorized into PE and non-PE groups.
  • Quantification of M1 (CD40+) and M2 (CD163+) macrophage subtypes using surface marker expression.
  • CD68+ was used to identify all macrophages.

Main Results:

  • Lung injury was evident in malaria patients with PE.
  • CD40 (M1 macrophage) expression was significantly higher in the PE group (63.44%) compared to the non-PE group (53.22%).
  • No significant difference in CD163 (M2 macrophage) expression was observed between the PE and non-PE groups.

Conclusions:

  • Severe P. falciparum malaria with PE is characterized by M1 macrophage polarization in lung tissues.
  • Characterizing macrophage subtypes in malaria infection offers potential insights for developing therapies to reduce lung damage.
  • Targeting M1 macrophages may be a therapeutic avenue for managing lung complications in severe malaria.

Related Concept Videos